Show simple item record

Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets

dc.contributor.authorPavlidis, Nicholasen
dc.creatorPavlidis, Nicholasen
dc.date.accessioned2018-06-22T09:54:14Z
dc.date.available2018-06-22T09:54:14Z
dc.date.issued2012
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42252
dc.description.abstractCancer of unknown primary sites (CUP) is a compilation of various malignant entities-the majority of which behave aggressively and carry poor prognosis. CUP is classified into two different clinicopathological groups: the unfavourable (poor-prognosis) and the favourable (good-prognosis) group. Patients with favourable subsets are treated relevant to the hidden primary tumour chemotherapy regimens and/or radiotherapy. These patients exhibit better responses and prolonged survival. On the other hand, patients of unfavourable subsets are treated with various chemotherapy combinations of platinum- or taxane-containing regimens. Unfortunately, responses and overall survival in this group of CUP patient are not very promising. Several independent prognostic factors have been associated with survival of CUP patients. Since CUP is not an unknown disease, emerging therapeutic innovations are warranted. © The author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.en
dc.language.isoengen
dc.sourceAnnals of Oncologyen
dc.subjectArticleen
dc.subjectAntineoplastic agenten
dc.subjectCisplatinen
dc.subjectCyclophosphamideen
dc.subjectDoxorubicinen
dc.subjectEtoposideen
dc.subjectFluorouracilen
dc.subjectHumanen
dc.subjectMitomycinen
dc.subjectNeoplasmsen
dc.subjectAdenocarcinomaen
dc.subjectHumansen
dc.subjectBreast canceren
dc.subjectCancer survivalen
dc.subjectCarboplatinen
dc.subjectPaclitaxelen
dc.subjectPriority journalen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectDrug efficacyen
dc.subjectGemcitabineen
dc.subjectTaxoidsen
dc.subjectTreatment outcomeen
dc.subjectPrognosisen
dc.subjectCancer stagingen
dc.subjectDocetaxelen
dc.subjectErlotiniben
dc.subjectMetastasisen
dc.subjectOverall survivalen
dc.subjectCancer prognosisen
dc.subjectCancer radiotherapyen
dc.subjectBone metastasisen
dc.subjectEpirubicinen
dc.subjectFolinic aciden
dc.subjectIrinotecanen
dc.subjectPlatinum complexen
dc.subjectCarcinomaen
dc.subjectClinical featureen
dc.subjectLymphatic metastasisen
dc.subjectHistopathologyen
dc.subjectDisease associationen
dc.subjectTreatment responseen
dc.subjectTreatmenten
dc.subjectBevacizumaben
dc.subjectAltretamineen
dc.subjectSquamous cell carcinomaen
dc.subjectCancer of unknown primary siteen
dc.subjectUnknown primaryen
dc.subjectCancer localizationen
dc.subjectProstate specific antigenen
dc.subjectNeuroendocrine tumoren
dc.subjectCervical lymph nodeen
dc.subjectPeritoneum canceren
dc.subjectClinical effectivenessen
dc.subjectCancer of unknown primaryen
dc.subjectAnthracyclinesen
dc.subjectColon adenocarcinomaen
dc.subjectOvary carcinomaen
dc.subjectPlatinumen
dc.subjectVindesineen
dc.subjectCapecitabine plus oxaliplatinen
dc.subjectClinicopathological subsetsen
dc.subjectLiver canceren
dc.titleOptimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsetsen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1093/annonc/mds317
dc.description.volume23
dc.description.issueSUPPL. 10en
dc.description.startingpagex282
dc.description.endingpagex285
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record